NLRP3 and osteoarthritis: Given the role of IL-1β in diseases such as type 2 diabetes [8], gout [7] and osteoarthritis [37], which all involve NLRP3, a small molecule such as CRID3 could have promise therapeutically and be an alternative to IL-1β biologics such as the anti-IL-1β antibody Canakinumab and the IL-1 Trap Rilonacept.